At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
PEP005 (ingenol mebutate) Gel, 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
In Brief
A Phase 2 clinical trial evaluating PEP005 (ingenol mebutate) Gel, 0.05% and Vehicle Gel for Actinic Keratosis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartMar 2009
Primary CompletionJun 2009
TodayJul 2026
First PostedFeb 26, 2009
Enrollment StartMar 1, 2009
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.3 years ago
Interventions
PEP005 (ingenol mebutate) Gel, 0.05%drug
PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
Vehicle Geldrug
Vehicle Gel once daily for 2 consecutive days